Tech Company Financing Transactions
Crescendo Bioscience Funding Round
Myriad Genetics participated in a $25 million funding round for Crescendo Bioscience. The round was announced by the company on 9/8/2011.
Transaction Overview
Company Name
Announced On
9/8/2011
Transaction Type
Debt
Amount
$25,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The $25 million investment by Myriad Genetics is non-dilutive capital that is structured as long term debt and is accompanied by a three-year option to acquire Crescendo Bioscience for cash at a predetermined multiple of revenue based on the growth rate of Crescendo Bioscience at the time of option exercise. The option allows Crescendo Bioscience to continue to operate independently and may be exercised after Crescendo Bioscience attains a minimum revenue milestone.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
341 Oyster Point Blvd
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Not Recorded
Overview
Crescendo Bioscience is developing a broad range of quantitative, objective diagnostic tools to provide Rheumatologists with deeper clinical insights to more effectively manage patients with autoimmune and inflammatory diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 9/8/2011: Crescendo Bioscience venture capital transaction
Next: 9/8/2011: Wildcat Discovery Technologies venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs